Current AMD laser therapies will dwindle in growing US ophthalmic surgical market
This article was originally published in Clinica
The US market for energy-based ophthalmic surgical systems totalled nearly $1.7bn in 2013 and is expected to experience healthy, mid-single digit growth over the next half-decade. The use of these systems is predicted to increase in refractive surgery and the treatment of cataracts, glaucoma and diabetic retinopathy. But while the incidence of age-related macular degeneration (AMD) is expected to increase significantly, then number of laser-based procedures like retinal photocoagulation and photodynamic therapy this field will decline due to its limited effectiveness and the increasing end-user adoption of anti-VEGF therapy.